GLRX3 and hepatocellular carcinoma: Notably, higher combinatory mRNA expressions of BOLA2 with GLRX3 were associated with poorer OS in HCC patients (HR = 1.56, 95% CI: 1.1-2.22, P = 8.1E − 4 and P = 2.7E − 8, respectively, Figure 8).